United States: Food, Drugs, Healthcare, Life Sciences

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

Recent Enforcement Cases In China Life Sciences Compliance

Chinese regulators have issued updates on enforcement cases targeting former officials who had responsibility for the life sciences industry, including those who served in the National Medical Products Administration (NMPA), which plays a role similar to the U.S. Food and Drug Administration.

United States Healthcare

AP

Arnold & Porter

The NIH-Proposed 15 Percent Indirect Cost Rate Cap Is Out – For Now

The U.S. Court of Appeals for the First Circuit on January 6, 2026, upheld a district court's decision to permanently enjoin and vacate guidance (Guidance)...

United States Healthcare

HK

Holland & Knight

FDA Is Open To The Idea Of Possible Regulatory Flexibility For Cell And Gene Therapies On A Case-by-Case Basis…Where Appropriate

Yesterday, FDA announced "Flexible Requirements for Cell and Gene Therapies to Advance Innovation."

United States Healthcare

HP

Hyman, Phelps, & McNamara

Telehealth Update: Telehealth Flexibilities, Convictions And Indictment, And 2026 Outlook

The end of 2025 saw several notable developments for the telehealth industry with early 2026 poised to potentially challenge the industry with the impending expiration of the short-term extension of the Medicare telehealth flexibilities.

United States Healthcare

M

Mintz

When Pass-Through Isn't Pass-Through: PBM GPOs And The Reengineering Of Rebates

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

National Pharmacy Benefit Manager Implements Direct-to-Consumer Model

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

2026 J.P. Morgan Healthcare Conference Preview: Dealmaking, Capital, And Strategic Themes To Watch

United States Healthcare

FH

Foley Hoag LLP

OIG's Latest Advisory Opinion: When Is A Discount A "Discount"?

United States Healthcare

PL

Polsinelli LLP

State AG News: Research Funding, Non-Profit Fraud, Underage Sales (January 1-7, 2026)

United States Healthcare

CM

Crowell & Moring LLP

Healthcare Trends & Transactions: 2025 Year In Review

United States Healthcare

BB

Bass, Berry & Sims

OIG Analyzes Market Share Rebates And Bundled Discounts Under The Discount Safe Harbor

United States Healthcare

BB

Bass, Berry & Sims

DOT Random Drug And Alcohol Testing Rates For 2026

United States Healthcare

JL

Jackson Lewis P.C.

2026 Healthcare Private Equity Outlook & Trends

United States Healthcare

BB

Bass, Berry & Sims

Digesting The New Dietary Guidelines With Key Takeaways For Regulated Entities

United States Healthcare

AG

Akin Gump Strauss Hauer & Feld LLP

Artificial Intelligence — A Blessing With Boundaries (Video)

United States Technology

MB

Michael Best

December 2025 Crypto Update: New Changes And Challenges In U.S. Regulation Of Digital Assets

United States Technology

B

Benesch Friedlander Coplan & Aronoff LLP

What Honeybees Have Taught Me About Dispute Resolution

United States Litigation

J

JAMS

Food Venture Financing News – Weekly Issue No. 263

United States Healthcare

DW

Davis Wright Tremaine

Countdown To Jan. 1, 2026: Preparing For California's New AI Training Data Transparency Obligations

United States Technology

FK

Frankfurt Kurnit Klein & Selz

See more

Highlighted Content

Plausibility At The EPO – An Update On G2/21

United States Healthcare

D

Dehns

Infringement Of Repurposed Drug Patents And Skinny Labelling – Where Does The Balance Lie In The United States Today?

United States Healthcare

D

Dehns

Infringement Of Repurposed Drug Patents And Skinny Labelling – Where Does The Balance Lie In Europe Today?

United States Healthcare

D

Dehns

How Good Does A Copy Need To Be?

United States Healthcare

D

Dehns

Supplementary Protection Certificates – European Patent Term Extensions

United States Healthcare

D

Dehns

How Much Experimental Data Is Needed For Patent Applications In Europe?

United States Healthcare

D

Dehns

The Silent Treatment: The EPO's Approach To Non-therapeutic Methods Encompassing Therapeutic Effects

United States Healthcare

D

Dehns

Implications Of The Genetic Technology (Precision Breeding) Bill On The Life Science IP Sector

United States Healthcare

D

Dehns

Protection For Plant Varieties In Europe And The UK Post-Brexit

United States Healthcare

D

Dehns

Best Practice For Invention Harvesting

United States Healthcare

D

Dehns

Food and Drugs Law

Recent Enforcement Cases In China Life Sciences Compliance

Chinese regulators have issued updates on enforcement cases targeting former officials who had responsibility for the life sciences industry, including those who served in the National Medical Products Administration (NMPA), which plays a role similar to the U.S. Food and Drug Administration.

United States Healthcare

AP

Arnold & Porter

FDA Is Open To The Idea Of Possible Regulatory Flexibility For Cell And Gene Therapies On A Case-by-Case Basis…Where Appropriate

Yesterday, FDA announced "Flexible Requirements for Cell and Gene Therapies to Advance Innovation."

United States Healthcare

HP

Hyman, Phelps, & McNamara

When Pass-Through Isn't Pass-Through: PBM GPOs And The Reengineering Of Rebates

For decades, Pharmacy Benefit Managers (PBMs) have positioned themselves as indispensable intermediaries in the prescription drug supply chain.

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

National Pharmacy Benefit Manager Implements Direct-to-Consumer Model

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

OIG's Latest Advisory Opinion: When Is A Discount A "Discount"?

United States Healthcare

PL

Polsinelli LLP

DOT Random Drug And Alcohol Testing Rates For 2026

United States Healthcare

JL

Jackson Lewis P.C.

Digesting The New Dietary Guidelines With Key Takeaways For Regulated Entities

United States Healthcare

AG

Akin Gump Strauss Hauer & Feld LLP

Drug Prices Fell. Premiums Rose. Where Did The Money Go?

United States Healthcare

JW

Jones Walker

Healthcare Trend Report: A Review Of The Pharmacy And Drug Supply Chain Sectors

United States Healthcare

HK

Holland & Knight

See more

Life Sciences, Biotechnology & Nanotechnology

FDA Is Open To The Idea Of Possible Regulatory Flexibility For Cell And Gene Therapies On A Case-by-Case Basis…Where Appropriate

Yesterday, FDA announced "Flexible Requirements for Cell and Gene Therapies to Advance Innovation."

United States Healthcare

HP

Hyman, Phelps, & McNamara

Turning Insight Into Action: A Life Sciences Playbook For 2026

Looking back on 2025, one word comes to mind: resiliency. The life sciences sector has taken some hits, but it kept moving. Public markets are showing real signs of life again.

United States Commercial

PL

Polsinelli LLP

Telehealth Update: Telehealth Flexibilities, Convictions And Indictment, And 2026 Outlook

The end of 2025 saw several notable developments for the telehealth industry with early 2026 poised to potentially challenge the industry with the impending expiration of the short-term extension...

United States Healthcare

M

Mintz

Holland & Knight Health Dose: January 6, 2026

United States Healthcare

HK

Holland & Knight

FDA Request For Information Signals New Path For VC Firms And Their Portfolio Companies In Federal Contracting

United States Healthcare

CM

Crowell & Moring LLP

Issue Brief: State-Level Medicaid Fraud In Focus

United States Healthcare

PL

Polsinelli LLP

CMS Launches Five New Models At The End Of 2025: Looks To Advance ACCESS, BALANCE, MAHA ELEVATE, GLOBE And GUARD In 2026

United States Healthcare

AG

Akin Gump Strauss Hauer & Feld LLP

Food Industry Braces For MAHA And Other Challenges In 2026

United States Healthcare

WR

Wiley Rein

Prescribing/Dispensing "Outside The Usual Course Of Professional Practice:" Trend, Coincidence Or Passing Fancy?

United States Healthcare

HP

Hyman, Phelps, & McNamara

See more

Healthcare

Recent Enforcement Cases In China Life Sciences Compliance

Chinese regulators have issued updates on enforcement cases targeting former officials who had responsibility for the life sciences industry, including those who served in the National Medical Products Administration (NMPA), which plays a role similar to the U.S. Food and Drug Administration.

United States Healthcare

AP

Arnold & Porter

Protecting The AI Advantage: Why Patents Are A Critical Growth And Risk-Management Tool For Digital Health Platforms

For CEOs, general counsels, and CTOs, the question is no longer whether patents matter. The question is whether the company has an intentional strategy to identify, capture, and deploy intellectual property in alignment with product and corporate goals.

United States IP

FL

Foley & Lardner

The NIH-Proposed 15 Percent Indirect Cost Rate Cap Is Out – For Now

The U.S. Court of Appeals for the First Circuit on January 6, 2026, upheld a district court's decision to permanently enjoin and vacate guidance (Guidance)...

United States Healthcare

HK

Holland & Knight

Telehealth Update: Telehealth Flexibilities, Convictions And Indictment, And 2026 Outlook

United States Healthcare

M

Mintz

When Pass-Through Isn't Pass-Through: PBM GPOs And The Reengineering Of Rebates

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

National Pharmacy Benefit Manager Implements Direct-to-Consumer Model

United States Healthcare

BI

Buchanan Ingersoll & Rooney PC

CMS LEAD Model Cracks Door Open To Cannabis Conversation

United States Cannabis

FH

Foley Hoag LLP

2026 J.P. Morgan Healthcare Conference Preview: Dealmaking, Capital, And Strategic Themes To Watch

United States Healthcare

FH

Foley Hoag LLP

OIG's Latest Advisory Opinion: When Is A Discount A "Discount"?

United States Healthcare

PL

Polsinelli LLP

See more

Latest Videos

See more

Episode 37: Chanda Center For Health: Reimagining Access To And Delivery Of Long-term Disability Care (Podcast)

FL

Foley & Lardner

Strategic Synergy At Atlantic Health: Saad Ehtisham On How Leadership Alignment Fuels Transformation (Video)

AM

Alvarez & Marsal

Album 9: Track 12 Steady On – Trilliant Health (Part 2) (Podcast)

PL

Polsinelli LLP

The Big, Beautiful Webinar Series: Strategic Planning For Post-Acute/LTC Providers (Video)

SM

Sheppard Mullin Richter & Hampton

Navigating Health Plan M&A: Strategies For Success In The Medicare Advantage Market (Podcast)

RG

Ropes & Gray LLP

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More